Dr. Keck joined The Jackson Laboratory in 2014 and is the Vice President of Innovation and Product Development. He is also the first JAX President’s Innovation Fellow. His Ph.D. and postdoctoral fellowship focused on understanding and discovering the molecular components for replication and pathogenesis of viruses, such as coronavirus and vaccinia virus, the vaccine strain of smallpox.
Prior to joining JAX, Keck spent over 20 years working in biotechnology and pharmaceutical drug discovery. During this time, Keck actively drove oncology, metabolic, and inflammatory disease projects through phase I, II, and III clinical trials. At JAX, Keck has been instrumental in the development of multiple humanized NSG strains to study the adaptive and innate immune system roles in oncology and related drug discovery. He is currently working to expand the utility of the humanized NSG platform to other therapeutic areas including autoimmune and inflammatory diseases. Most recently, he developed an innovative approach to quickly and reliably understand the efficacy and safety of therapeutics targeting cancer as they relate to Cytokine Release Syndrome.
We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.